{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CGRP+antibody",
    "query": {
      "intervention": "CGRP antibody"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T11:54:18.260Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05503082",
      "title": "Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Headache, Migraine"
      ],
      "interventions": [
        {
          "name": "Ubrogepant 50 MG [Ubrelvy]",
          "type": "DRUG"
        },
        {
          "name": "Ubrogepant 100 MG [Ubrelvy]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chicago Headache Center & Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 164,
      "start_date": "2022-09-06",
      "completion_date": "2024-11",
      "has_results": false,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-09-10T11:54:18.260Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Naperville, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Naperville",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05503082"
    },
    {
      "nct_id": "NCT07159750",
      "title": "Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Migraine",
        "Episodic Migraine",
        "Chronic Migraine, Headache"
      ],
      "interventions": [
        {
          "name": "CGRP antibody or gepant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital Universitari Vall d'Hebron Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2024-01-02",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-09-10T11:54:18.260Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07159750"
    },
    {
      "nct_id": "NCT07599228",
      "title": "Using Virtual Reality to Teach Mindfulness to People With Migraine",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Migraine Disorders",
        "Migraine With Aura",
        "Migraine Without Aura",
        "Episodic Migraine"
      ],
      "interventions": [
        {
          "name": "ACT therapy delivered by REACT NeuroVR headset",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 160,
      "start_date": "2026-08-24",
      "completion_date": "2031-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-10T11:54:18.260Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Chestnut Hill, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        },
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07599228"
    },
    {
      "nct_id": "NCT06701526",
      "title": "A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Eptinezumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 164,
      "start_date": "2024-12-18",
      "completion_date": "2026-09-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-10T11:54:18.260Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • San Marcos, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06701526"
    },
    {
      "nct_id": "NCT04158752",
      "title": "Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Trigeminal Neuralgia",
        "Glossopharyngeal Neuralgia"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2020-07-24",
      "completion_date": "2023-01-04",
      "has_results": true,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-09-10T11:54:18.260Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04158752"
    },
    {
      "nct_id": "NCT05937152",
      "title": "A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Eptinezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-01",
      "completion_date": "2025-11",
      "has_results": false,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-09-10T11:54:18.260Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05937152"
    },
    {
      "nct_id": "NCT05162027",
      "title": "Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Temporomandibular Disorders"
      ],
      "interventions": [
        {
          "name": "Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 5,
      "start_date": "2022-05-26",
      "completion_date": "2023-01-03",
      "has_results": true,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-09-10T11:54:18.260Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05162027"
    },
    {
      "nct_id": "NCT06018025",
      "title": "NDPH Biomarker Study in Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "New Persistent Daily Headache"
      ],
      "interventions": [
        {
          "name": "CGRP antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 38,
      "start_date": "2024-04-15",
      "completion_date": "2025-05-29",
      "has_results": false,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-09-10T11:54:18.260Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06018025"
    },
    {
      "nct_id": "NCT04098250",
      "title": "Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-Traumatic Headache"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 6,
      "start_date": "2021-01-04",
      "completion_date": "2024-01-10",
      "has_results": true,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-09-10T11:54:18.260Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04098250"
    }
  ]
}